EMMA Emmaus Life Sciences, Inc.
Pharmaceutical Preparations · OTC · SEC CIK 822370 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY18.1%
TTM net income YoY-19.2%
TTM EPS YoY-8.3%
Revenue 3-yr CAGR-21.0%
Net income 3-yr CAGR—
Margins
Gross margin92.1%
Operating margin24.8%
Net margin-61.9%
FCF margin—
EBITDA margin25.2%
Returns
ROE—
ROA-45.1%
ROIC (approx.)—
Asset turnover0.73x
Leverage & solvency
Liabilities / assets487.1%
Debt / equity—
Current ratio0.06x
Interest coverage0.44x
Cash quality & payout
Operating cash flow / net income-0.22x
Accruals ratio-54.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $12.45M | $16.65M |
| Cost of revenue | $857,000 | $1.20M |
| Gross profit | $11.60M | $15.45M |
| R&D expense | $313,000 | $657,000 |
| SG&A expense | $8.18M | $10.69M |
| Operating income | $231,000 | -$1.89M |
| Interest expense | $7.13M | $5.49M |
| Pretax income | -$7.48M | -$6.42M |
| Income tax | $9,000 | $29,000 |
| Net income | -$7.49M | -$6.45M |
| EBITDA | $270,000 | -$1.87M |
| EPS (basic) | -0.12 | -0.10 |
| EPS (diluted) | -0.12 | -0.10 |
| Weighted avg. shares (diluted) | 64.04M | 63.23M |
| Balance sheet | ||
| Cash & equivalents | $2.13M | $1.39M |
| Receivables | $2.80M | $2.62M |
| Inventory | $1.55M | $1.64M |
| Current assets | $7.75M | $6.77M |
| PP&E, net | $113,000 | $46,000 |
| Total assets | $21.44M | $23.60M |
| Current liabilities | $69.07M | $63.55M |
| Long-term debt | $27.13M | $28.96M |
| Total debt | $27.13M | $28.96M |
| Total liabilities | $85.04M | $80.08M |
| Shareholders' equity | -$63.61M | -$56.48M |
| Net debt | $25.00M | $27.58M |
| Shares outstanding | 70.19M | 63.87M |
| Cash flow statement | ||
| Operating cash flow | -$11,000 | -$2.29M |
| Capital expenditure | $1,000 | $12,000 |
| Free cash flow | -$12,000 | -$2.30M |
| Investing cash flow | $2.17M | $2.50M |
| Financing cash flow | -$1.43M | -$1.35M |
| Depreciation & amortization | $39,000 | $22,000 |
| Stock-based compensation | $25,000 | $256,000 |
Free plan shows the latest 2 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.